Scientific Posters & Practice Pearl Posters
Tuesday, September 12
10:00-10:40 am
DIABETIC RETINOPATHY
301	Evaluation of portable digital camera for screening of Diabetic retinopathy in primary care and satellite clinics K. V. Chalam, MD, PhD
302	Pars Plana Vitrectomy Using a 25-Gauge System in Patients with PDR John P. Denny, MD
303	Effect of Intracameral Bevacizumab on Neovascularization of The Iris Swati Agarwal, MD
304	Intravitreal Bevacizumab (Avastin) for PDR J. Fernando Arevalo, MD, FACS
305	IVT in the Treatment of Diabetic Maculopathy Leyla S. Atmaca, MD
306	Vitreous surgery for recalcitrant NVG in PDR Guruprasad S. Ayachit, MS
307	Effects of Triamcinolone Injection on Macular Functions in DME Yavuz Bardak, MD
308	Phacoemulsification-PPV versus PPV alone in PDR Yavuz Bardak, MD
309	A Simple Predictor of Vitrase® Efficacy for Successful Laser Treatment in Patients with Diabetes and Severe Vitreous Hemorrhage Abdhish R. Bhavsar, MD
310	Alterations in Ocular Perfusion after IVT Injection for DME Osman Cekic, MD, PhD
311	Objective Quantification of Disappearance of Plaque-like Hard Exudates in DME after IVT Injection Osman Cekic, MD, PhD
312	Efficacy of intravitreal bevacizumab for severe nonproliferative , PDR and active photocoagulated retinopathy Jans Fromow-Guerra, MD, PhD
313	Ultrastructural Morphometry of the ILM in the Laboratory Universal Computer Image Analysis System Bohdana Kalvodova, MD
314	Response of Different Patterns of DME to Treatment with a Sustained-Release Dexamethasone Posterior-Segment Drug-Delivery System Baruch D. Kuppermann, MD, PhD
315	Use of Perfluorocarbon Liquid During Diabetic Vitrectomy Janice C. Law, MD
316	Subthreshold Diode Micropulse Panretinal Photocoagulation for PDR Jeffrey K. Luttrull, MD
317	Screening Diabetic Retinopathy in Burgundy with an Itinerant Non-mydriatic Camera Laure Malvitte, MD
318	Occult Ipsilateral Neurovascular Stenosis in Asymmetric Diabetic Retinopathy and Rubeosis Nader Moinfar, MD
319	Use of Silicone Oil for Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Serguei V Nossov, MD
320	DME Before and After IVT Injection Alireza Ramezani, MD
321	An OCT stepped Approach to DME Pietro Rossi, MD
322	Microelements in Eyes with Proliferative Diabetic, Traumatic Retinopathy and Detached Retina Andriy Sergienko, MD
323	Evaluation of Air as a Retinal Tamponade during Vitrectomy in eyes with Diabetic Tractional or Combined Tractional Rhegmatogenous Detachment Ashraf Shaarawy, MD
324	Rate of Vitrectomy in the Fellow Eye of Patients Undergoing Primary Diabetic Vitrectomy Ashish G. Sharma, MD
325	Intravitral Injection of Triamcinolone for the Treatment of DME Ashraf Shoukry, MD
326	Nerve Fiber Layer Lose Following Laser Photocoagulation in Diabetic Patients Using OCT Mahmoud Soliman, MD
327	Regression of Severe Neovascularization of the Disc after Intravitreal Bevacizumab Treatment Ubeyt Inan Umit, MD
MACULAR SURGERY
328	Macular hole due to Terson’s syndrome Willemine De Vries Knoppert, MD
329	Adult Vitelliform Macular Dystrophy treated with Bevacizumab Naomi S. Falk, MD
330	Safety and Efficacy of Intravitreal Bevacizumab for Subfoveal CNV in Pathologic Myopia Myriam Lucia Hernandez-Rojas, MD
331	Anatomic and Functional Results in MH Surgery Miguel Angel Quiroz-Reyes, MD
332	Unusual Aetiologies of Full Thickness MH Mahmoud Soliman
333	OCT Characteristics of ERM in Neurofibromatosis 2 Amy C Schefler, MD
334	Pars Plana Vitrectomy for ERM associated with Combined Hamartoma of the Retina and Retinal Pigment Epithelium extending to the Fovea Edmund Y.M. Wong, MD
RETINAL VASCULAR DISEASE AND ONCOLOGY
335	The Complications after Intravitreal Injection of Triamcinolone Acetonide Dong Heun Nam, MD
336	A meta-analysis of visual outcome following IVT Acetonide for ME in Retinal Vascular Disorders Ron A. Adelman, MD, MPH
337	Absence of histologic retinal toxicity with standard clinical doses of intravitreal bevacizumab in a rabbit model Sophie J Bakri, MD
338	Particular Profile for Idiopathic CRVO in Young Adults Frank J. Becquet, MD, PhD
339	Pegaptanib for the Treatment of Iris Neovascularization Chris Bergstrom, MD
340	ICG Mediated Phototrombosis of a Large Retinal Hemangioblastoma in Von Hippel-Lindau Disease Enrico Bertelli, MD
341	The effect of HIF-1O expression on hypoxemic bovine retinal endothelial cells and intervention Aijun Deng, MD
342	Pars Plana Vitrectomy on 23-Years Old Man with CRVO Dagmar Dotrelova, MD, PhD
343	Central Retinal Artery Occlusion Hussein Elgendy, MD
344	Central Serous Chorioretinopathy Following Unusual Routes of Administration of Exogenous Steroids Manjot Gill, MD
345	Intravitreal Bevacizumab (Avastin) as Treatment for ME in Vein Occlusions Jose Luis Guerrero-Naranjo, MD
346	Transvitreal Radial Optic Neurotomy Hans Hoerauf, MD
347	Unilateral Nonischemic CRVO in Young Adults Christos D. Kalogeropoulos, MD
348	Intravitreal Bevacizumab (Avastin) as Salvage Treatment of Refractory CNV and ME from Retinal Vascular Disease Michael M Lai, MD, PhD
349	Direct Tissue Plasminogen Activator Infusion into a Branch Retinal Vein in Patients with CRVO Sun-Taek Lim, MD
350	Ophthalmic Arterial Fibrinolysis with Urokinase for Recent Severe CRVO: Initial Experience Jose Luis Rosales Meneses, MD, PhD
351	Management of Coats Disease: Study of 29 Cases Florence Metge, MD
352	Functional and Anatomical Investigations in Racemose Hemangioma Carsten H. Meyer, MD
353	Intravitreal Bevacizumab for Idiopathic CRVO in a 12 Year-old Girl Jared S Nielsen, MD
354	Vitrectomy for Non-clearing Non-Diabetic Vitreous Haemorrhage at The Western Eye Hospital Joseph Park, MBBS, FRANZCO
355	Intravitreal Triamcinolone for Acute CRVO: A Randomized Clinical Trial Alireza Ramezani
356	Treatment of Uncontrolled Neovascular Glaucoma in African-Americans by Vitrectomy, Laser, Air-Fluid Exchange, C3F8 and Pars Plana Baerveldt Implant Diana Reeves, MD
357	CRVO - anticoagulant Treatment with Warfarin Jiri Rehak, MD
358	Histopathologic evaluation of Optic Neurotomy with Microvitreoretinal Blade and Excimer Laser in Cadaver Eyes Masoud Soheilian, MD
359	The ubiquity of VEGF in retinal diseases as determined by clinical response to bevacizumab (Avastin®) Edgar L. Thomas, MD
360	The Effect of an IVT Injection in ME Secondary to Parafoveal Telangiectasis Type 2A Lihteh Wu, MD
361	Long-term Outcome of Pars Plana Glaucoma Valve Implants in Neovascular Glaucoma of Retinal Vascular Origin: an Asian Experience Yeo Kim-Teck, MD